OptiNose (OPTN) News Today $9.38 -0.04 (-0.42%) Closing price 04:00 PM EasternExtended Trading$9.37 -0.01 (-0.15%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Geode Capital Management LLC Has $576,000 Stake in OptiNose, Inc. (NASDAQ:OPTN)Geode Capital Management LLC reduced its position in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,167 shares of the company's stock after selling 1,May 5 at 3:07 AM | marketbeat.comAcorn Capital Advisors LLC Makes New $2.82 Million Investment in OptiNose, Inc. (NASDAQ:OPTN)Acorn Capital Advisors LLC acquired a new stake in OptiNose, Inc. (NASDAQ:OPTN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 422,813 shares of the company's stock, valued at approximately $2,8May 4 at 7:13 AM | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Shares Sold by MVM Partners LLCMVM Partners LLC cut its holdings in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 973,684 shares of the company's stock after selling 13,631,579 shares during the quarter. OptiMay 3 at 8:10 AM | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Nantahala Capital Management LLCNantahala Capital Management LLC reduced its stake in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 986,031 shares of the cApril 30, 2025 | marketbeat.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNApril 29, 2025 | businesswire.comGMT Capital Corp Decreases Stock Position in OptiNose, Inc. (NASDAQ:OPTN)GMT Capital Corp reduced its position in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,047 shares of the company's stock after selling 1,036,655 shareApril 25, 2025 | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Short Interest UpdateOptiNose, Inc. (NASDAQ:OPTN - Get Free Report) saw a significant decline in short interest in March. As of March 31st, there was short interest totalling 191,700 shares, a decline of 29.5% from the March 15th total of 271,800 shares. Currently, 2.4% of the shares of the stock are sold short. Based on an average daily volume of 93,100 shares, the days-to-cover ratio is currently 2.1 days.April 20, 2025 | marketbeat.comAster Capital Management DIFC Ltd Reduces Holdings in OptiNose, Inc. (NASDAQ:OPTN)Aster Capital Management DIFC Ltd cut its stake in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,898 shares of the company's stock after selling 54April 13, 2025 | marketbeat.comBank of New York Mellon Corp Sells 170,507 Shares of OptiNose, Inc. (NASDAQ:OPTN)Bank of New York Mellon Corp decreased its holdings in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,178 shares of the company's stock after selling 170,507 shares during the quarter.March 31, 2025 | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Position Reduced by Easterly Investment Partners LLCEasterly Investment Partners LLC lessened its position in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 98.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 46,667 shares of the company's stock after selling 2,312,572 shares duringMarch 29, 2025 | marketbeat.comOptinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational IncomeMarch 28, 2025 | msn.comOptiNose (NASDAQ:OPTN) Releases Quarterly Earnings Results, Beats Expectations By $0.67 EPSOptiNose (NASDAQ:OPTN - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.67. The firm had revenue of $21.47 million for the quarter, compared to analysts' expectations of $21.02 million.March 28, 2025 | marketbeat.comOptinose reports Q4 EPS (3c) vs ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comOptinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsMarch 26, 2025 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersMarch 25, 2025 | morningstar.comOptiNose (NASDAQ:OPTN) Cut to "Hold" at Piper SandlerPiper Sandler downgraded shares of OptiNose from a "strong-buy" rating to a "hold" rating in a research report on Thursday.March 23, 2025 | marketbeat.comPiper Sandler Reiterates Neutral Rating for OptiNose (NASDAQ:OPTN)Piper Sandler reissued a "neutral" rating and issued a $9.00 price objective (down from $15.00) on shares of OptiNose in a research note on Friday.March 22, 2025 | marketbeat.comOptiNose (NASDAQ:OPTN) Given Neutral Rating at HC WainwrightHC Wainwright reissued a "neutral" rating and issued a $9.00 target price (down previously from $18.00) on shares of OptiNose in a report on Friday.March 22, 2025 | marketbeat.comOptinose downgraded to Neutral from Buy at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNMarch 21, 2025 | businesswire.comOptinose downgraded to Neutral from Overweight at Piper SandlerMarch 21, 2025 | markets.businessinsider.comOptinose downgraded to Hold from Buy at Lake StreetMarch 21, 2025 | markets.businessinsider.comLake Street Downgrades OptiNose (OPTN)March 21, 2025 | msn.comWhy OptiNose Inc. (OPTN) Surged On Thursday?March 21, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of ShareholdersMarch 21, 2025 | globenewswire.comOptiNose (NASDAQ:OPTN) Downgraded by Lake Street Capital to "Hold"Lake Street Capital cut OptiNose from a "buy" rating to a "hold" rating in a report on Thursday.March 21, 2025 | marketbeat.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | gurufocus.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | prnewswire.comOPTN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Optinose, Inc. Is Fair to ShareholdersMarch 20, 2025 | tmcnet.comOptiNose climbs after take-private deal with Paratek PharmaMarch 20, 2025 | msn.comOptinose Shares Soar After Merger Agreement With Paratek Pharmaceuticals: Retail Sentiment Takes FlightMarch 20, 2025 | msn.comShareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public ShareholdersMarch 20, 2025 | businesswire.comOptinose Cancels Fourth Quarter and Full Year 2024 Earnings CallMarch 19, 2025 | globenewswire.comParatek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)March 19, 2025 | globenewswire.comOptiNose (NASDAQ:OPTN) shareholders have endured a 90% loss from investing in the stock five years agoMarch 13, 2025 | finance.yahoo.comOptinose to Announce Q4 and Full-Year 2024 Financial Results on March 20, 2025March 13, 2025 | msn.comOptiNose (OPTN) Projected to Post Quarterly Earnings on ThursdayOptiNose (NASDAQ:OPTN) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comOptinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | markets.businessinsider.comOptiNose, Inc. (NASDAQ:OPTN) CEO Sells $33,729.04 in StockOptiNose, Inc. (NASDAQ:OPTN - Get Free Report) CEO Ramy A. Mahmoud sold 6,376 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the sale, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.March 5, 2025 | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) CEO Ramy A. Mahmoud Sells 6,376 SharesMarch 5, 2025 | insidertrades.comOptiNose trading resumesMarch 4, 2025 | markets.businessinsider.comShort Interest in OptiNose, Inc. (NASDAQ:OPTN) Grows By 16.2%OptiNose, Inc. (NASDAQ:OPTN - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 247,800 shares, an increase of 16.2% from the January 15th total of 213,300 shares. Based on an average daily trading volume, of 65,200 shares, the short-interest ratio is currently 3.8 days. Approximately 3.1% of the company's shares are short sold.February 17, 2025 | marketbeat.comOptinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCEJanuary 18, 2025 | msn.comOptinose, Inc.: Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 MillionJanuary 16, 2025 | finanznachrichten.deOptinose price target adjusted for stock split at Lake StreetJanuary 16, 2025 | markets.businessinsider.comLake Street Capital Has Lowered Expectations for OptiNose (NASDAQ:OPTN) Stock PriceLake Street Capital cut their target price on OptiNose from $45.00 to $17.00 and set a "buy" rating on the stock in a research report on Thursday.January 16, 2025 | marketbeat.comLake Street Remains a Buy on Optinose (OPTN)January 16, 2025 | markets.businessinsider.comOptinose Reports Q4 XHANCE Net Product Revenue; Sees Continued Growth In Year AheadJanuary 15, 2025 | markets.businessinsider.comOptinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 MillionJanuary 15, 2025 | globenewswire.comHC Wainwright Forecasts OptiNose FY2029 EarningsOptiNose, Inc. (NASDAQ:OPTN - Free Report) - Research analysts at HC Wainwright issued their FY2029 EPS estimates for OptiNose in a note issued to investors on Friday, January 3rd. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of $1.41 per share for the year. HCJanuary 6, 2025 | marketbeat.com Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address OPTN Media Mentions By Week OPTN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPTN News Sentiment▼1.400.69▲Average Medical News Sentiment OPTN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPTN Articles This Week▼52▲OPTN Articles Average Week Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revance Therapeutics News Olema Pharmaceuticals News COMPASS Pathways News Oruka Therapeutics News Immutep News Aerovate Therapeutics News SNDL News Allogene Therapeutics News Autolus Therapeutics News Checkpoint Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPTN) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump's tariffs on China have caused a ripple effect across global markets. But in crypto? They've lit a fu...Crypto 101 Media | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OPTN Stock Free OPTN Stock Alerts